Navigation Links
Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer

WALTHAM, Mass., Nov. 1, 2013 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. today announced the promotion of John S. Pallies to chief financial officer from vice president, finance and administration, and co-founder Peter Ordentlich, Ph.D., to chief technology officer from vice president, translational medicine. Both appointments are effective Nov.1, 2013.

"These promotions are recognition of the exceptional work John and Peter have done helping Syndax develop to the point of being ready to begin a Phase 3 trial of entinostat in patients with advanced breast cancer," said Arlene M. Morris, Syndax's chief executive officer. "John has been leading the financial operations of Syndax for more than six years and Peter co-founded the company based on scientific discoveries at the Salk Institute for Biological Studies. We are confident John's financial insight and strategic aptitude and Peter's unique clinical and scientific expertise will help Syndax continue successful development of entinostat for the treatment of breast cancer and other malignancies."

Mr. Pallies joined Syndax in 2007 with more than a decade of experience in biotech, high-tech start-ups and management consulting focused on developing corporate and financial infrastructures and managing multiple business operations. Prior to co-founding Syndax in 2005, Dr. Ordentlich was a scientist at the Salk Institute for Biological Studies in La Jolla, California, working with Dr. Ronald M. Evans to identify small molecules as potential therapeutics and evaluating synergistic combinations of histone deacetylase inhibitors and nuclear receptor ligands.

About Syndax Pharmaceuticals

Syndax is late stage biopharmaceutical company focused on the development and commercialization of its lead product candidate, entinostat, an epigenetic therapy for treatment-resistant cancers. Entinostat was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration.

Corporate Contact:
Bob Goodenow
Chief Business Officer
Syndax Pharmaceuticals
(781) 419-1418

Media Contacts:
David Schull or Matt Middleman, M.D.
Russo Partners
(212) 845-4271
(212) 845-4272

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndaxs Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer
2. Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries
3. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
4. Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
5. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
6. Medela Promotes Human Milk Consumption in NICUs to Address Health Risks Associated with Prematurity and Improve Infant Health
7. SynteractHCR Promotes Education to Take Time and Cost out of Drug Development with ICD+ Webinar Series
8. Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer
9. Lower Extremity Functional Electrical Stimulation Cycling Promotes Physical & Neurological Recovery in Chronic Spinal Cord Injury
10. OncoSec Medical Promotes Veronica Vallejo to Chief Financial Officer
11. Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes
Post Your Comments:
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
Breaking Medicine News(10 mins):